Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.44) by 77.27 percent. This is a 70.59 percent increase over losses of $(0.34) per share from the same period last year.
Raymond James Initiates Coverage On Netstreit with Strong Buy Rating, Announces Price Target of $24
Raymond James analyst RJ Milligan initiates coverage on Netstreit (NYSE:NTST) with a Strong Buy rating and announces Price Target of $24.
